Chronic medication use may increase in breast cancer survivors after cancer treatment
the ONA take:
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment. The study was published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers sought to characterize the patterns of medication use by survivors of early-stage breast cancer from diagnosis to 1 year after chemotherapy.
Researchers enrolled 107 patients diagnosed between December 2011 and June 2014, all participants were treated at a single center. Medication use data was retrieved from prescription databases and records from the National Electronic Health Records.
Results showed that 46.7% of participants developed non-cancer comorbidities, including hypertension, hyperlipidemia, and diabetes.
The most common chronic medication types before chemotherapy were calcium channel blockers and lipid-modifying agents. Their use persisted during and after chemotherapy. The most commonly used post-chemotherapy medication was hormonal therapy.
Researchers found that there was a statistically significant increase in the average number of chronic disease medication classes prescribed to patients between the pre-chemotherapy and chemotherapy periods, as well as between the chemotherapy and post-chemotherapy periods (P < 0.0001).
“This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results,” the authors concluded.
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|